Aligos TherapeuticsInitiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)

2022-12-15

siRNA临床结果

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530).

“siRNA drugs targeting HBsAg production have generally been well tolerated and have consistently lowered HBsAg levels, demonstrating the potential to become a cornerstone therapy to achieve functional cure in CHB,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “The team has made excellent progress over the past two months advancing ALG-125755 through the single ascending dose (SAD) portion of the study in healthy volunteers, where doses up to 100 mg have been evaluated. This has enabled us to advance into CHB subjects ahead of schedule. We plan to evaluate additional CHB cohorts receiving single or multiple doses of ALG-125755 throughout the coming year to identify a dose regimen to advance into combination studies. Additionally, we plan to share available study data in healthy volunteers and CHB subjects at scientific conferences throughout 2023.”

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

机构